HBM's (HKG:2142) profit plunged to $2.7 million in 2024 from $22.8 million in 2023.
The drug company logged zero earnings per share during the year compared with $0.03 in the previous year, according to a Monday filing with the Hong Kong bourse.
Revenue shrank to $38.1 million from $89.5 million a year earlier.